Conv. Plasma
Nigella Sativa
Peg.. Lambda

All ivermectin studies
Meta analysis
Home COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  

Variation in therapeutic strategies for the management of severe COVID-19 in India- A nationwide cross-sectional survey

Jagiasi et al., The International Journal of Clinical Practice, doi:10.1111/ijcp.14574
Jun 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Survey of medication use for severe COVID-19 in India, showing 33% adoption of ivermectin as of January 2021.
Jagiasi et al., 25 Jun 2021, peer-reviewed, 19 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Variation in therapeutic strategies for the management of severe COVID‐19 in India: A nationwide cross‐sectional survey
Bharat Jagiasi, Prashant Nasa, Gunjan Chanchalani, Ahsan Ahmed, Ajith Kumar Ak, Kanwalpreet Sodhi, Kishore Mangal, Manoj K Singh, Nitesh Gupta, Prasanna U Bidkar, Ranvir S Tyagi, Reshu G Khanikar, Swagata Tripathy, Swapna Khanzode, Kesavarapu Subba Reddy, Saurabh Saigal, Vijay Anand Sivakumar, Yash Javeri, Seema S Tekwani
International Journal of Clinical Practice, doi:10.1111/ijcp.14574
Aim: During the pandemic of coronavirus disease 2019 (COVID-19), the physicians are using various off-label therapeutics to manage COVID-19. We undertook a crosssectional survey to study the current variation in therapeutic strategies for managing severe COVID-19 in India. Methods: From January 4 to January 18, 2021, an online cross-sectional survey was conducted among physicians involved in the management of severe COVID-19. The survey had three sections: 1. Antiviral agents, 2. Immunomodulators, and 3. Adjuvant therapies. Results: 1055 respondents (from 24 states and five union territories), of which 64.2% were consultants, 54.3% working in private hospitals, and 39.1% were from critical care medicine completed the survey. Remdesivir (95.2%), antithrombotics (94.2%),
prescribed antibiotics with severity of COVID-19 (58.3%) or increased inflammatory markers (56.4%) were preferred indications. There was significant variation in the use of adjuvant therapies with specialists from critical care medicine preferred use of antibiotics in severe and critical COVID-19, while anaesthesiologists preferred vitamins in all patients of COVID-19. Bacterial co-infections are uncommon in COVID-19 and vary from 3.5% at the time of admission to 15% among hospitalised patients. 28 A recent guideline on antimicrobials in COVID-19, recommended a restrictive approach and empirical antibiotics to be considered only if clinical, imaging and biochemical markers suggest a bacterial co-infection. The de-escalation of antibiotics within 48 hours is suggested if representative cultures or antigen tests excluded bacterial co-infection. 29 The authors did not recommend any empirical antibiotic regimen and advised to use community or hospital-acquired pneumonia guidelines while starting antibiotics and using local antimicrobial surveillance. 29 Recently, the RECOVERY trial found no role of azithromycin in the treatment of hospitalised COVID-19 patients. 30 The prepublication release from the PRINCIPAL trial using azithromycin or doxycycline for 14 days showed no significant benefit in time to recovery or hospitalisation. 31 NIH does not recommend vitamin C in COVID-19 because of insufficient data. 32 There are ongoing trials on intravenous vitamin C in..
Agarwal, Mukherjee, Kumar, Convalescent plasma in the management of moderate covid-19 in adults in India:open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ
Alhazzani, Evans, Alshamsi, Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update, Crit Care Med
Armstrong, Kane, Cook, Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies, Anaesthesia
Asch, Sheils, Islam, Variation in US hospital mortality rates for patients admitted with COVID-19 during the first 6 months of the pandemic, JAMA Intern Med
Beigel, Tomashek, Dodd, Remdesivir for the treatment of covid-19 -final report, N Engl J Med
Berlin, Gulick, Martinez, Severe covid-19, N Engl J Med
Borczuk, Salvatore, Seshan, COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City, Mod Pathol
Charan, Kaur, Bhardwaj, Snapshot of COVID-19 related clinical trials in India, Indian J Clin Biochem
Chatterjee, Is India missing COVID-19 deaths?, Lancet
Chow, Khanna, Kethireddy, Aspirin use is associated with decreased mechanical ventilation, ICU admission, and inhospital mortality in hospitalized patients with COVID-19, Anesth Analg
Dong, Du, Gardner, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect Dis
Gopalan, Misra, COVID-19 pandemic and challenges for socio-economic issues, healthcare and National Health Programs in India, Diabetes Metab Syndr
Grasselli, Greco, Zanella, Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy, JAMA Intern Med
He, Yi, Zhu, Estimation of the basic reproduction number, average incubation time, asymptomatic infection rate, and case fatality rate for COVID-19: meta-analysis and sensitivity analysis, J Med Virol
Horby, Lim, Emberson, Dexamethasone in hospitalized patients with covid-19 -preliminary report, N Engl J Med
Janiaud, Axfors, Schmitt, Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis, JAMA
Joshi, Parkar, Ansari, Role of favipiravir in the treatment of COVID-19, Int J Infect Dis
Lim, Subramaniam, Reddy, Case fatality rates for patients with COVID-19 requiring invasive mechanical ventilation. a meta-analysis, Am J Respir Crit Care Med
Murdaca, Pioggia, Negrini, Vitamin D and Covid-19: an update on evidence and potential therapeutic implications, Clin Mol Allergy
News, PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19
Nice, COVID-19 rapid evidence summary: Tocilizumab for COVID-19
Nih, The COVID-19 Treatment Guidelines Panel's Statement on the Use of Ivermectin for the Treatment of COVID-19
Onder, Rezza, Brusaferro, Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy, JAMA
Pan, Peto, Henao-Restrepo, Repurposed antiviral drugs for covid-19 -Interim WHO Solidarity trial results, N Engl J Med
Parr, Time to Reassess Tocilizumab's Role in COVID-19 Pneumonia, JAMA Intern Med
Sieswerda, De Boer, Bonten, Recommendations for antibacterial therapy in adults with COVID-19 -an evidence based guideline, Clin Microbiol Infect
Sterne, Murthy, Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis, JAMA
Wise, Covid-19: Arthritis drugs improve survival in intensive care patients, shows study, BMJ
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention, JAMA
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop